These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 10638992)
1. Sample size calculation for clinical trials: the impact of clinician beliefs. Fayers PM; Cuschieri A; Fielding J; Craven J; Uscinska B; Freedman LS Br J Cancer; 2000 Jan; 82(1):213-9. PubMed ID: 10638992 [TBL] [Abstract][Full Text] [Related]
2. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Cuschieri A; Weeden S; Fielding J; Bancewicz J; Craven J; Joypaul V; Sydes M; Fayers P Br J Cancer; 1999 Mar; 79(9-10):1522-30. PubMed ID: 10188901 [TBL] [Abstract][Full Text] [Related]
3. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
4. Surgical treatment of advanced gastric cancer: Japanese perspective. Sasako M; Saka M; Fukagawa T; Katai H; Sano T Dig Surg; 2007; 24(2):101-7. PubMed ID: 17446702 [TBL] [Abstract][Full Text] [Related]
5. Integrating expert opinions with clinical trial data to analyse low-powered subgroup analyses: a Bayesian analysis of the VeRDiCT trial. Thirard R; Ascione R; Blazeby JM; Rogers CA BMC Med Res Methodol; 2020 Dec; 20(1):300. PubMed ID: 33302878 [TBL] [Abstract][Full Text] [Related]
6. Trial Steering Committees in randomised controlled trials: A survey of registered clinical trials units to establish current practice and experiences. Conroy EJ; Harman NL; Lane JA; Lewis SC; Murray G; Norrie J; Sydes MR; Gamble C Clin Trials; 2015 Dec; 12(6):664-76. PubMed ID: 26085545 [TBL] [Abstract][Full Text] [Related]
7. Use of methods for specifying the target difference in randomised controlled trial sample size calculations: Two surveys of trialists' practice. Cook JA; Hislop JM; Altman DG; Briggs AH; Fayers PM; Norrie JD; Ramsay CR; Harvey IM; Vale LD; Clin Trials; 2014 Jun; 11(3):300-308. PubMed ID: 24603006 [TBL] [Abstract][Full Text] [Related]
8. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Cuschieri A; Fayers P; Fielding J; Craven J; Bancewicz J; Joypaul V; Cook P Lancet; 1996 Apr; 347(9007):995-9. PubMed ID: 8606613 [TBL] [Abstract][Full Text] [Related]
9. Quality control of lymph node dissection in the Dutch Gastric Cancer Trial. de Steur WO; Hartgrink HH; Dikken JL; Putter H; van de Velde CJ Br J Surg; 2015 Oct; 102(11):1388-93. PubMed ID: 26313463 [TBL] [Abstract][Full Text] [Related]
11. D2 Lymphadenectomy for Gastric Adenocarcinoma: Long-term Results and the Impact of Surgeon Experience on the Survival Rates. Tudor S; Dumitrascu T; Manuc M; Trandafir B; Ionescu M; Popescu I; Herlea V; Vasilescu C Chirurgia (Bucur); 2018; 113(6):772-779. PubMed ID: 30596365 [No Abstract] [Full Text] [Related]
12. Resection for gastric cancer in the community. van de Velde CJ Semin Oncol; 2005 Dec; 32(6 Suppl 9):S90-3. PubMed ID: 16399441 [TBL] [Abstract][Full Text] [Related]
13. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice. Jachno K; Heritier S; Wolfe R BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924 [TBL] [Abstract][Full Text] [Related]
14. Comparison of long term survival outcomes between D1+ and D2 lymph node dissection for ≥ pT2 or pN+ gastric carcinoma: A large scale case-control study using propensity score matching. Kang JH; Ryu SY; Jung MR; Jeong O Eur J Surg Oncol; 2020 Jul; 46(7):1239-1246. PubMed ID: 32331983 [TBL] [Abstract][Full Text] [Related]
15. Community engagement and involvement in Ghana: conversations with community stakeholders to inform surgical research. Kroese K; Ofori BA; Abdulai DR; Monahan M; Prah A; Tabiri S Res Involv Engagem; 2021 Jul; 7(1):50. PubMed ID: 34225824 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? Reddavid R; Sofia S; Chiaro P; Colli F; Trapani R; Esposito L; Solej M; Degiuli M World J Gastroenterol; 2018 Jan; 24(2):274-289. PubMed ID: 29375213 [TBL] [Abstract][Full Text] [Related]
17. [Total gastrectomy for gastric cancer: can the type of lymphadenectomy condition the long-term results?]. Di Martino N; Izzo G; Cosenza A; Vicenzo L; Monaco L; Torelli F; Basciotti A; Brillantino A; Marra A Suppl Tumori; 2005; 4(3):S84-5. PubMed ID: 16437920 [TBL] [Abstract][Full Text] [Related]
18. D2 or not D2? The gastrectomy question. Lewis WG; Edwards P; Barry JD; Khan S; Dhariwal D; Hodzovic I; Allison MC; Shute K Gastric Cancer; 2002; 5(1):29-34. PubMed ID: 12021857 [TBL] [Abstract][Full Text] [Related]
19. Long-term survival with non-proportional hazards: results from the Dutch Gastric Cancer Trial. Putter H; Sasako M; Hartgrink HH; van de Velde CJ; van Houwelingen JC Stat Med; 2005 Sep; 24(18):2807-21. PubMed ID: 16134134 [TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Degiuli M; Sasako M; Ponti A; Vendrame A; Tomatis M; Mazza C; Borasi A; Capussotti L; Fronda G; Morino M; Br J Surg; 2014 Jan; 101(2):23-31. PubMed ID: 24375296 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]